Cannabidiol Market Report 2026

The cannabidiol market size has grown exponentially in recent years. It will grow from $15.44 billion in 2025 to $20.34 billion in 2026 at a compound annual growth rate (CAGR) of 31.7%. The growth in the historic period can be attributed to legalization of medical cannabis in key regions, growth of alternative medicine usage, rising consumer awareness of cbd benefits, expansion of hemp cultivation, availability of cbd extraction technologies.

The cannabidiol market size is expected to see exponential growth in the next few years. It will grow to $62.61 billion in 2030 at a compound annual growth rate (CAGR) of 32.5%. The growth in the forecast period can be attributed to increasing acceptance of cbd in healthcare, rising investments in cannabinoid research, expansion of regulated cbd retail channels, growing demand for plant-based therapeutics, increasing standardization of cbd formulations. Major trends in the forecast period include increasing adoption of cbd-based therapeutics, rising demand for wellness and nutraceutical products, growing use in personal care formulations, expansion of pharmaceutical-grade cbd products, enhanced focus on regulatory compliance.

The increasing prevalence of neurological disorders is expected to drive the growth of the cannabidiol market. Neurological disorders, affecting the central and peripheral nervous systems - including the brain, spinal cord, and nerves - can be managed with cannabidiol, which helps regulate calcium homeostasis and reduce neuroinflammation. For instance, in March 2023, according to the Alzheimer’s Association, a US-based nonprofit organization, approximately 6.7 million Americans aged 65 and older were living with Alzheimer’s dementia, projected to rise to 13.8 million by 2060. Therefore, the growing prevalence of neurological disorders is fueling demand for cannabidiol.

Major companies in the cannabidiol market are focusing on product innovations, such as epilepsy therapeutics, to improve seizure management. Epilepsy therapeutics are drugs specifically developed to prevent, control, or treat epilepsy and improve patient outcomes. For instance, in January 2024, Akumentis Healthcare Ltd., an India-based pharmaceutical company, launched Clasepi, a DCGI-approved cannabidiol-based prescription drug for managing seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and Tuberous Sclerosis Complex in patients aged one year and older. Clasepi contains less than 0.1% THC, ensuring it is non-psychotropic, and has shown effectiveness where traditional antiseizure medications are inadequate.

In April 2025, Xebra Brands Ltd., a Canada-based CBD products company, acquired a 100% stake in BSK Holdings Inc., a US-based CBD company, for an undisclosed amount. Through this acquisition, Xebra aimed to expand its presence in the U.S. CBD market, accelerating entry into North America’s largest hemp/CBD market. BSK Holdings specializes in e-commerce sales of premium CBD products, including popular brands like Keoni and AMMA.

Major companies operating in the cannabidiol market are Endoca BV, Cannoid LLC, Medical Marijuana Inc., Folium Biosciences, Elixinol Global Limited, NuLeaf Naturals LLC, Isodiol International Inc., Pharmahemp d.o.o., Canopy Growth Corp., CV Sciences Inc., Medterra LLC, Cronos Group, CBD American Shaman LLC, Aphria Inc., Maricann Inc., Tilray Inc., Organigram Holding Inc., CannTrust Holdings Company, Charlotte's Web Holdings Inc., Aurora Cannabis Inc., GW Pharmaceuticals PLC, Green Roads, HempMeds PX LLC, Eco Sciences, Bluebird Botanicals, HempFusion Inc., Kannaway LLC, Lazarus Naturals, Kazmira LLC, HempLife Today LLC.

North America was the largest region in the cannabidiol market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cannabidiol market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cannabidiol market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cannabidiol market consists of sales of full spectrum CBD, broad spectrum CBD and CBD isolate forms of cannabidiol products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.